Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market
Trinity Biotech (Nasdaq: TRIB) has unveiled CGM+, an AI-native continuous glucose monitoring platform targeting the $260 billion AI wearable market. The next-generation wearable biosensor combines glucose monitoring with heart activity, temperature, and physical activity tracking in a single modular device.
The CGM+ platform features a minimally invasive electrochemical glucose sensor and proprietary needle-free technology, designed to reduce disposable components and lower care costs. The company anticipates a commercial launch in mid-2026, targeting both clinical and consumer health markets.
The global CGM market is projected to grow from $13.28B in 2025 to $28.72B by 2030 (16.68% CAGR). Trinity Biotech plans multiple revenue streams, including device sales, AI analytics subscriptions, and strategic partnerships with healthcare providers, insurers, and digital health platforms.
Trinity Biotech (Nasdaq: TRIB) ha presentato CGM+, una piattaforma di monitoraggio continuo del glucosio basata su intelligenza artificiale, rivolta al mercato degli indossabili AI da 260 miliardi di dollari. Il biosensore indossabile di nuova generazione combina il monitoraggio del glucosio con l’attività cardiaca, la temperatura e il tracciamento dell’attività fisica in un unico dispositivo modulare.
La piattaforma CGM+ integra un sensore elettrochimico del glucosio minimamente invasivo e una tecnologia proprietaria senza ago, progettata per ridurre i componenti usa e getta e abbassare i costi di assistenza. L’azienda prevede un lancio commerciale a metà 2026, con un focus sia sul mercato clinico che su quello della salute consumer.
Il mercato globale del CGM è stimato crescere da 13,28 miliardi di dollari nel 2025 a 28,72 miliardi entro il 2030 (CAGR del 16,68%). Trinity Biotech punta a diverse fonti di ricavo, tra cui la vendita dei dispositivi, abbonamenti ad analisi AI e partnership strategiche con operatori sanitari, assicuratori e piattaforme di salute digitale.
Trinity Biotech (Nasdaq: TRIB) ha lanzado CGM+, una plataforma de monitoreo continuo de glucosa nativa de IA que apunta al mercado de dispositivos wearables con IA de 260 mil millones de dólares. El biosensor portátil de próxima generación combina el monitoreo de glucosa con la actividad cardíaca, la temperatura y el seguimiento de la actividad física en un solo dispositivo modular.
La plataforma CGM+ cuenta con un sensor electroquímico de glucosa mínimamente invasivo y tecnología patentada sin aguja, diseñada para reducir los componentes desechables y disminuir los costos de atención. La compañía anticipa un lanzamiento comercial a mediados de 2026, dirigido tanto a mercados clínicos como de salud para consumidores.
Se proyecta que el mercado global de CGM crecerá de 13.28 mil millones de dólares en 2025 a 28.72 mil millones para 2030 (CAGR del 16.68%). Trinity Biotech planea múltiples fuentes de ingresos, incluyendo ventas de dispositivos, suscripciones de análisis de IA y asociaciones estratégicas con proveedores de salud, aseguradoras y plataformas de salud digital.
트리니티 바이오텍 (나스닥: TRIB)은 2600억 달러 규모의 AI 웨어러블 시장을 겨냥한 AI 기반 연속 혈당 모니터링 플랫폼인 CGM+를 공개했습니다. 차세대 웨어러블 바이오센서는 혈당 모니터링과 심장 활동, 체온, 신체 활동 추적을 하나의 모듈형 장치에 결합했습니다.
CGM+ 플랫폼은 최소 침습 전기화학 혈당 센서와 독자적인 바늘 없는 기술을 특징으로 하며, 일회용 부품을 줄이고 치료 비용을 낮추도록 설계되었습니다. 회사는 2026년 중반 상업 출시를 목표로 임상 및 소비자 건강 시장을 겨냥하고 있습니다.
글로벌 CGM 시장은 2025년 132.8억 달러에서 2030년 287.2억 달러로 성장할 것으로 예상되며(연평균 성장률 16.68%), 트리니티 바이오텍은 기기 판매, AI 분석 구독, 의료 제공자, 보험사 및 디지털 건강 플랫폼과의 전략적 파트너십 등 다양한 수익원을 계획하고 있습니다.
Trinity Biotech (Nasdaq : TRIB) a dévoilé CGM+, une plateforme de surveillance continue du glucose native en IA, ciblant le marché des wearables IA de 260 milliards de dollars. Le biosenseur portable de nouvelle génération combine la surveillance du glucose avec l’activité cardiaque, la température et le suivi de l’activité physique dans un seul appareil modulaire.
La plateforme CGM+ intègre un capteur électrochimique du glucose peu invasif et une technologie propriétaire sans aiguille, conçue pour réduire les composants jetables et diminuer les coûts de soins. L’entreprise prévoit un lancement commercial à la mi-2026, visant les marchés cliniques et de la santé grand public.
Le marché mondial du CGM devrait passer de 13,28 milliards de dollars en 2025 à 28,72 milliards en 2030 (TCAC de 16,68%). Trinity Biotech prévoit plusieurs sources de revenus, notamment la vente d’appareils, les abonnements aux analyses IA et des partenariats stratégiques avec des prestataires de soins, des assureurs et des plateformes de santé numérique.
Trinity Biotech (Nasdaq: TRIB) hat CGM+ vorgestellt, eine KI-native kontinuierliche Glukoseüberwachungsplattform, die den 260 Milliarden Dollar schweren KI-Wearable-Markt adressiert. Der Wearable-Biosensor der nächsten Generation kombiniert Glukoseüberwachung mit Herzaktivität, Temperatur und körperlicher Aktivität in einem modularen Gerät.
Die CGM+-Plattform verfügt über einen minimalinvasiven elektrochemischen Glukosesensor und eine proprietäre nadelfreie Technologie, die darauf ausgelegt ist, Einwegkomponenten zu reduzieren und die Versorgungskosten zu senken. Das Unternehmen plant eine Markteinführung Mitte 2026, mit Fokus auf klinische und Endverbrauchermärkte im Gesundheitsbereich.
Der globale CGM-Markt wird voraussichtlich von 13,28 Mrd. USD im Jahr 2025 auf 28,72 Mrd. USD im Jahr 2030 wachsen (CAGR 16,68%). Trinity Biotech plant mehrere Einnahmequellen, darunter Geräteverkauf, Abonnements für KI-Analysen und strategische Partnerschaften mit Gesundheitsdienstleistern, Versicherern und digitalen Gesundheitsplattformen.
- Revolutionary AI-native platform combining glucose, cardiovascular, temperature, and activity monitoring in one device
- Proprietary needle-free technology reduces disposable components and lowers care costs
- Multiple revenue streams potential through device sales, AI analytics subscriptions, and partnerships
- Targeting high-growth markets: CGM ($28.72B by 2030), AI Healthcare ($200B by 2030), and Wearable AI ($260B by 2032)
- Commercial launch not expected until mid-2026
- Product still in development phase with pending trial results
- Faces competition in established CGM market
- Significant regulatory approvals likely needed before commercialization
Insights
Trinity Biotech's CGM+ represents a strategic pivot into the high-growth AI wearables market with multiple potential revenue streams.
Trinity Biotech's announcement of CGM+ marks a significant strategic expansion beyond traditional diagnostics into the rapidly growing AI wearables space. The platform combines a minimally invasive glucose sensor with additional metrics tracking (heart activity, temperature, physical activity) in a single modular device designed specifically for AI integration.
What sets this platform apart is its multi-modal approach – rather than just tracking glucose like traditional CGMs, it creates a comprehensive health monitoring ecosystem that could generate value from both hardware sales and data services. The modular design with fewer disposable components addresses sustainability concerns while potentially lowering costs compared to market leaders.
The company is targeting a mid-2026 commercial launch, positioning itself at the intersection of three high-growth markets: the CGM sector (
The platform's dual-market approach – serving both clinical and consumer wellness segments – creates multiple potential revenue streams beyond one-time device sales, including AI analytics subscriptions and strategic partnerships. This recurring revenue model, if successfully executed, could transform Trinity's business fundamentals and growth trajectory.
With development in later stages and pre-pivotal trial completion, the next 12-18 months will be critical in determining whether Trinity can successfully execute this ambitious pivot into the competitive wearable health technology space.
WILSONVILLE, Ore. and DUBLIN, July 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the
CGM+ combines sustainability with user-friendly design, featuring a compact wearable and reusable sensor applicator.
Unlike traditional CGMs focused solely on glucose monitoring, CGM+ integrates an ultra-thin minimally invasive electrochemical glucose sensor with continuous monitoring of heart activity, body temperature and physical activity—all within a single, sleek and user-friendly modular wearable device. This multimodal data stream is being optimized for real-time AI analysis, to enable a deeper, more contextual understanding of metabolic and physiological health. Trinity Biotech has identified these expanded data points as critical to gain insights into essential metabolic factors, including sleep, stress, and physical activity. Trinity Biotech’s vision is to combine medical-grade monitoring and consumer wellness insights, through the CGM+ platform, positioning Trinity Biotech at the forefront of a new category of intelligent wearables.
Trinity Biotech’s proprietary needle-free glucose sensor technology facilitates the collection of expanded data points from a single modular wearable device. The Company’s latest innovative design utilises this technology to provide a solution that not only reduces the number of disposable components and waste, but also significantly lowers the cost of care compared to current leading market products.
Modular wearable engineered for real-time, AI-native insights—CGM+ designed to integrate glucose, heart activity, temperature, and motion tracking in one seamless, sustainable wearable.
“CGM+ is not just a device—it’s a proprietary data engine we are building for the AI health ecosystem,” said John Gillard, CEO of Trinity Biotech. “We believe this technology can power the next wave of personalized, predictive, and preventative care—while opening up entirely new commercial pathways for Trinity Biotech, from device sales to AI-driven data services. It will also position us to compete well beyond traditional diagnostics, at the intersection of chronic disease management, digital health and consumer wellness.”
Trinity Biotech’s CGM+ wearable biosensor designed to seamlessly integrate glucose, cardiovascular, temperature, and activity monitoring in one sleek modular device.
Purpose-Built for Real-Time AI-Driven Healthcare
As healthcare shifts toward precision medicine and continuous, real-world data collection, CGM+ is positioned to become a critical enabler of AI-based diagnostics, behavioural coaching, and chronic disease management. Now in the later stages of device development, CGM+ has been engineered from the ground up to serve as a foundational platform for AI-native health applications:
- Comprehensive Multi-sensor Intelligence: Combines glucose, cardiovascular, thermoregulation and physical activity data for a holistic view of health and wellness.
- Clinical and Consumer Lifestyle Use Cases: Designed to support both regulated clinical workflows and consumer wellness applications, bridging the gap between medical-grade monitoring and everyday health optimization.
Market Opportunity
- Global CGM Market: Projected to grow from
$13.28B in 2025 to$28.72B by 2030 (CAGR:16.68% )1 - AI in Healthcare: Forecast to reach approximately
$200B by 2030, growing at a37.6% CAGR2 - Wearable AI: Expected to surpass
$260B by 2032, growing at a27.0% CAGR3
CGM+ is uniquely positioned at the intersection of these high-growth sectors, and is being designed to offer a differentiated solution for both clinical and consumer health markets.
Strategic Outlook and Additional Revenue Opportunities
Trinity Biotech anticipates commercial launch of CGM+ in mid-2026, opening multiple revenue streams, including device sales, AI analytics subscriptions and strategic partnerships with healthcare providers, insurers and digital health platforms.
“CGM+ is the cornerstone of our vision for AI-native health monitoring,” added Gillard. “We’re not just adding a product—we’re building a scalable platform with recurring revenue potential that we believe can drive long-term growth across clinical and consumer markets.”
Trinity Biotech recently completed a further pre-pivotal trial of its upgraded glucose sensor technology and expects to issue key findings from this trial shortly.
For further information, please see the Company's CGM+ microsite: https://cgm.trinitybiotech.com
1 https://www.mordorintelligence.com/industry-reports/continuous-glucose-monitoring-market
2 https://www.mordorintelligence.com/industry-reports/artificial-intelligence-in-healthcare-market
3 https://www.fortunebusinessinsights.com/wearable-ai-market-109561
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
| Contact: | Trinity Biotech plc | RedChip Companies Inc. |
| Gary Keating, Ph.D | Dave Gentry, CEO | |
| (353)-1-2769800 | (1)-407-644-4256 | |
| TRIB@redchip.com | ||
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/03ec64b3-baf3-4d1c-8323-ddb34d9f333c
https://www.globenewswire.com/NewsRoom/AttachmentNg/728e5d44-7d29-4326-ad0e-73912c0b5b6a
https://www.globenewswire.com/NewsRoom/AttachmentNg/fdc94876-019a-4efc-9db0-552858dcdf77
FAQ
What is Trinity Biotech's new CGM+ platform and how is it different from traditional CGMs?
When will Trinity Biotech (TRIB) launch the CGM+ platform commercially?
What is the market potential for Trinity Biotech's CGM+ platform?
How does Trinity Biotech's CGM+ technology reduce healthcare costs?
What are the key features of Trinity Biotech's CGM+ platform?
